Letrozol +pharma

Letrozole, the active ingredient in Letrozol +pharma, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen production to limit tumor growth and improve disease‑free survival outcomes.

GNH USA supplies Letrozol +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to EU quality standards and provides reliable logistics for hospitals, pharmacies and procurement teams across multiple regions.

Letrozole is used in the management of hormone‑dependent breast cancer, targeting estrogen‑driven tumor pathways. - Hormone receptor‑positive breast cancer (adjuvant setting): reduces risk of disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer: slows disease progression and prolongs survival. - Neoadjuvant therapy in postmenopausal women: may shrink tumors prior to surgical resection.

Letrozole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: upset stomach and urge to vomit. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe liver injury: elevated enzymes or hepatitis. - Bone fracture: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: clot formation in lung vessels. - Anaphylaxis: rapid allergic reaction with breathing difficulty. - Elevated cholesterol: significant rise in blood lipid levels. - QT interval prolongation: potential cardiac rhythm disturbance.

Before initiating Letrozole therapy, several precautions should be considered to ensure safe use. - Assess hepatic function: evaluate liver enzymes prior to treatment. - Monitor bone health: perform baseline bone mineral density testing and consider calcium/vitamin D supplementation. - Review cardiovascular risk: check lipid profile and blood pressure regularly. - Avoid use in pregnancy: contraindicated in pregnant women due to potential fetal harm. - Evaluate drug interactions: consider concomitant medications that affect CYP3A4 metabolism. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Letrozole can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce Letrozole plasma levels. - Estrogen‑containing hormone therapy: antagonizes Letrozole’s anti‑estrogen effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Tamoxifen: concurrent use may alter metabolic pathways and affect efficacy. - Warfarin: Letrozole may enhance anticoagulant effect, requiring INR monitoring. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): potential modest impact on metabolism. - Statins: monitor lipid levels as Letrozole can raise cholesterol.